Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 6.443
Filter
1.
Rev. chil. cardiol ; 43(1): 9-21, abr. 2024. tab, graf
Article in Spanish | LILACS | ID: biblio-1559638

ABSTRACT

Introducción: La insuficiencia cardíaca (IC) tiene alta morbilidad y mortalidad. Su diagnóstico temprano en atención primaria de salud (APS) es un reto dada la baja especificidad de sus criterios clínicos y las limitaciones en acceso a técnicas diagnósticas. Objetivo: Analizar la prevalencia de IC, subtipos y pronóstico de pacientes con disnea y/o edema de extremidades inferiores que consultan en APS. Metodología: Se trata de un estudio prospectivo de 340 pacientes en APS, sin diagnóstico previo de IC. Se realizó una evaluación clínica, electrocardiograma, NT-proBNP "point-of-care", ecocardiografía con interpretación telemática por cardiólogos. Utilizando los algoritmos HFA-PEFF y H2FPEF se clasificaron los pacientes como :1) IC con fracción de eyección (FE) reducida (ICFER); 2) IC con FE preservada (ICFEP) y 3) pacientes sin diagnóstico de IC. Se efectuó un análisis de sobrevida de los diferentes grupos. Resultados: La prevalencia de ICFER fue 8%, ICFEP por HFA-PEFF 42% y por H2FPEF 8%. Los algoritmos sugieren efectuar un estudio complementario en el 47% con HFA-PEFF y 76% con H2FPEF (p<0.05). La sobrevida global a 36 meses fue 90±2% y cardiovascular 95±1%. Usando HFA-PEFF, los pacientes con IC tuvieron menor sobrevida que aquellos sin IC (HR 2.3, IC95% 1.14.9; p=0.029). No hubo diferencias de mortalidad con H2FPEF. Conclusiones: En pacientes de APS que consultan por disnea y/o edema de extremidades inferiores sometidos a evaluación con NT-proBNP y ecocardiografía, se observó una prevalencia de IC de hasta 50%, 8% de ICFER y 42% de ICFEP. La caracterización de IC utilizando HFA-PEFF está asociada al pronóstico vital.


Background: Heart failure (HF) is a condition associated with high morbidity and mortality. Its early diagnosis in primary health care (PHC) represents a substantial challenge, considering its non-specific clinical manifestations and the limitations on timely access to diagnostic techniques. Objective: To evaluate the prevalence of HF, characterize subtypes and determine the prognosis of patients consulting in PHC for dyspnea Edema of the lower extremities. Methods: Prospective study in 340 patients who consulted in PHC, without previous diagnosis of HF. Clinical evaluation, electrocardiogram, NT-proBNP point-ofcare and echocardiography with telematic interpretation by cardiologists were performed. Using the HFA-PEFF and H2FPEF algorithms patients were classified as: 1) HF with reduced ejection fraction (HFREF); 2) HF with preserved ejection fraction (HFPEF) and 3) No HF. Actuarial survival analyses were performed. Results: We observed a prevalence of HFREF of 8%, high probability of HFPEF by HFA-PEFF in 42% and by H2FPEF in 8%. Intermediate probability of HFPEF, requiring complementary study, was observed in 47% of patients with HFA-PEFF and 76% of patients with H2FPEF (p<0.05). Overall survival at 36 months was 90±2% and cardiovascular survival at 36 months was 95±1%. Using HFA-PEFF, patients with HF presented lower overall survival compared to patients with no HF (HR 2.3, 95%CI 1.1-4.9; p=0.029). We did not observe mortality differences with H2FPEF. Conclusions: In patients consulting for dyspnea and/or lower extremity edema at PHC and undergoing evaluation with NT-proBNP and echocardiography, we observed a HF prevalence of 50%. HF classification through HFA-PEFF was associated with lower survival rates.


Subject(s)
Humans , Male , Female , Aged , Primary Health Care , Heart Failure/diagnosis , Heart Failure/epidemiology , Prognosis , Stroke Volume , Survival Analysis , Chile , Prevalence , Natriuretic Peptide, Brain/analysis , Heart Failure/classification
2.
Rev. chil. cardiol ; 43(1): 42-48, abr. 2024. ilus, graf
Article in Spanish | LILACS | ID: biblio-1559641

ABSTRACT

Introducción: La presencia de una vena cava superior izquierda persistente, durante el implante de electrodos endocavitarios para la resincronización cardíaca, representa una anomalía poco habitual de gran relevancia, que puede presentarse de forma inesperada durante el abordaje venoso superior habitual. Planteando desafíos técnicos en su implante y dudas sobre su eficacia o seguridad a corto y largo plazo; existiendo aislados casos publicados. Caso clínico: Presentamos un caso complejo con esta inusual anomalía llevado a implante de este dispositivo de forma exitosa, con funcionamiento normal durante su seguimiento de 7 años, llevado posteriormente a cambio de generador. Conclusiones: La vena cava superior izquierda persistente es la anomalía del retorno venoso cardiaco más frecuente, aunque su prevalencia es baja, presenta una gran relevancia en el implante y posicionamiento de electrodos endocavitarios necesarios para la terapia de resincronización cardiaca. Existe una evidencia creciente sobre su factibilidad y seguridad a corto y largo plazo a pesar de sus dificultades técnicas asociadas.


Introduction: The presence of a persistent left superior vena cava, during the implantation of endocavitary electrodes for cardiac resynchronization, represents an unusual anomaly of great relevance, which can occur unexpectedly during the usual superior venous approach. It constitutes a technical challenge in your implant and doubts about its effectiveness or safety in the short and long term. There are isolated published cases. We present a complex case with this unusual anomaly that led to successful implantation of this device, with a normal functio during its 7-year follow-up It was followed by uneventul generator change. Conclusions: Persistent left superior vena cava is the most common cardiac venous return anomaly. Although its prevalence is low, it is of great relevance in the implantation and positioning of endocavitary electrodes necessary for cardiac resynchronization therapy. There is growing evidence about its feasibility and safety in the short and long term despite.


Subject(s)
Humans , Male , Middle Aged , Cardiac Resynchronization Therapy/methods , Heart Failure
3.
Geriatr Gerontol Aging ; 18: e0000146, Apr. 2024.
Article in English | LILACS | ID: biblio-1566831

ABSTRACT

Objective: To map the dimensions of quality of life in patients with heart failure (HF) and sarcopenia. Methods: The scoping review will adhere to the JBI Manual for Evidence Synthesis methodology and will be reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR). Searches will encompass MEDLINE/PubMed, SCOPUS, EMBASE/Elsevier, LILACS, IBECS, BDENF (BVS), SciELO, Core Collection (Clarivate Analytics), CINAHL, Academic Search Premier (EBSCO), PsycINFO (APA), Cochrane Library, Epistemonikos, and academic search engines: Google Scholar and Bielefeld Academic Search Engine (BASE), without language or date restrictions. Inclusion criteria: Population ­ adults with HF and sarcopenia; Concept ­ Dimensions of quality of life including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression ­ defined based on the EQ-5D-3L questionnaire; Context ­ any health care setting. Two independent reviewers will select studies and extract data, with a third reviewer consulted in cases of discrepancies. Findings will be presented graphically with a narrative summary. Expected results: We aim to uncover key dimensions of quality of life in individuals with HF and sarcopenia through this scoping review. Anticipated outcomes include insights into mobility, self-care, usual activities, pain/discomfort, and anxiety/depression across diverse health care settings. Relevance: This review sheds light on the interplay between HF and sarcopenia and its impact on quality of life. The findings may guide interventions, inform evidence-based decision-making, and contribute to targeted strategies to improve the wellbeing of individuals managing both conditions. Review registration: Open Science Framework [https://archive.org/details/osf-registrations-jn387-v1]. (AU)


Subject(s)
Humans , Sarcopenia , Heart Failure , Quality of Life
5.
Article in Spanish | LILACS, CUMED | ID: biblio-1565595

ABSTRACT

Introducción: Se realizó una investigación descriptiva y prospectiva con la intención de definir el valor pronóstico del índice leucoglucémico en pacientes portadores de síndrome coronario agudo con elevación del ST. Objetivo: Valorar la importancia de la utilización del índice leucoglucémico como factor predictivo de complicaciones en el infarto agudo de miocardio con ST elevado. Métodos: Se estudió una muestra de 60 pacientes ingresados en la Unidad de Cuidados Intensivos del Hospital Clínico Quirúrgico Docente Amalia Simoni, de Camagüey, durante el año 2021, a los que se les llenó un cuestionario, de donde se obtuvieron: edad, color de la piel, antecedentes patológicos personales, hábitos tóxicos, complicaciones ocurridas, estado al alta y resultados del índice leucoglucémico. Los datos extraídos fueron manejados según estadística descriptiva, para obtener resultados en número y porciento, que conllevaron a las conclusiones finales. Resultados: Predominaron mujeres blancas mayores de 56 años de edad, hipertensas y diabéticas, asociadas al hábito de fumar en un gran porciento, con la aparición de múltiples complicaciones. También predominaron el cuadro de insuficiencia cardiaca y las arritmias en más de dos tercios de los casos, y hubo un número alto de fallecidos con índice leucoglucémico elevado. Conclusiones: Los resultados derivados de esta investigación apoyan el fundamento teórico-práctico de la utilización del índice leucoglucémico como predictor de complicaciones a corto plazo en el infarto agudo de miocardio con ST elevado, apreciado por su sencillez, amplia disponibilidad y bajo costo(AU)


Introduction: A descriptive and prospective research was carried out with the intention of defining the prognostic value of the leuko-glycemic index in patients carrying acute coronary syndrome with ST elevation. Objective: To assess the importance of the use of the leuko-glycemic index as a predictive factor of complications in acute myocardial infarction with elevated ST. Methods: A sample of 60 patient was studied; they entered the Intensive Care Unit of the Clinical Surgical Teaching Hospital Amalia Simoni, of Camaguey, during 2021, and filled out a questionnaire from which age, color of skin, personal pathological antecedents, toxic habits, complications, status at discharge and results of the leuko-glycemic index were obtained. The extracted data were managed according to descriptive statistic to obtain results in number and percentage, which led to the final conclusions. Results: White women over 56 years old, hypertensive and diabetic predominated, associated with smoking in a large percent, and with the appearance of multiple complications. Heart failure and arrhythmias also predominated in more than two thirds of the cases, and there were a high number of deaths with high leuko-glycemic index. Conclusions: The results derived from this research support the theoretical-practical foundation of the use of the leuko-glycemic index as a predictor of short term complications in acute myocardial infarction with elevated ST, appreciated for its simplicity, wide availability and low cost(AU)


Subject(s)
Humans , Male , Female , Heart Failure/complications , Heart Failure/epidemiology , Myocardial Infarction/mortality , Epidemiology, Descriptive , Prospective Studies
6.
Rev. latinoam. enferm. (Online) ; 32: e4227, 2024. graf
Article in English | LILACS, BDENF | ID: biblio-1569987

ABSTRACT

Abstract Objective: to describe factors of influence of telenursing on naturalistic decision making about self-care of people with heart failure during COVID-19. Method: this is a descriptive study with a qualitative approach, with 16 participants interviewed after hospitalization for decompensated heart failure. The data was collected using audio and video technology and submitted to content analysis, guided by the Situation-Specific Theory of Heart Failure Self-Care. Result: two thematic categories emerged from the analysis: Self-care as a decision-making process and Factors influencing decision-making, which describe tele-nursing as a support resource for people with heart failure, during changes in care in the pandemic period. Conclusion: it was possible to understand the relationship between telenursing and the establishment of a bond, in order to stimulate naturalistic decision-making by people with heart failure in their daily lives in a coherent way, leading to better health outcomes.


Resumo Objetivo: descrever fatores de influência da telenfermagem na tomada de decisão naturalista sobre o autocuidado de pessoas com insuficiência cardíaca durante a COVID-19. Método: estudo descritivo de abordagem qualitativa, com 16 participantes entrevistados após hospitalização pela descompensação da insuficiência cardíaca. Os dados foram coletados por tecnologia de áudio e vídeo e submetidos à análise de conteúdo, norteada pela Teoria de Situação Específica do Autocuidado da Insuficiência Cardíaca. Resultados: duas categorias temáticas emergiram da análise: Autocuidado como processo de tomada de decisão e Fatores que influenciam a tomada de decisão, as quais descrevem a telenfermagem como recurso de apoio à pessoa com insuficiência cardíaca, durante modificações de atendimento no período pandêmico. Conclusão: foi possível compreender a relação entre a telenfermagem e o estabelecimento de vínculo, de maneira a estimular a tomada de decisão naturalista pela pessoa com insuficiência cardíaca em seu cotidiano de forma coerente, impulsionando melhores resultados em saúde.


Resumen Objetivo: describir factores de influencia de la teleenfermería en la toma de decisión naturalista sobre el autocuidado de personas con insuficiencia cardíaca durante la pandemia de COVID-19. Método: estudio descriptivo de enfoque cualitativo, con 16 participantes entrevistados tras la hospitalización por la descompensación de la insuficiencia cardíaca. Los datos se recopilaron mediante tecnología de audio y vídeo y se sometieron a análisis de contenido, guiado por la Teoría de Situación Específica del Autocuidado de la Insuficiencia Cardíaca. Resultados: dos categorías temáticas surgieron del análisis: Autocuidado como proceso de toma de decisión y Factores que influyen en la toma de decisión, las cuales describen a la teleenfermería como recurso de apoyo a la persona con insuficiencia cardíaca, durante modificaciones de atención en el período pandémico. Conclusión: fue posible comprender la relación entre la teleenfermería y el establecimiento de vínculo, de manera a estimular la toma de decisión naturalista por la persona con insuficiencia cardíaca en su cotidianidad de forma coherente, impulsando mejores resultados en salud.


Subject(s)
Humans , Chronic Disease/therapy , Qualitative Research , Self-Management , Telemonitoring , COVID-19 , Heart Failure
7.
Rev. urug. cardiol ; 39(1): e402, 2024. ilus
Article in Spanish | LILACS, BNUY, UY-BNMED | ID: biblio-1565801

ABSTRACT

La congestión en pacientes con insuficiencia cardíaca representa una manifestación de diversos procesos estructurales y funcionales cardiovasculares, asociada a alta morbimortalidad y reducción de calidad de vida, se considera la principal causa de ingreso a hospitalización y reingreso por insuficiencia cardíaca. Durante las últimas décadas, se ha logrado un mejor entendimiento de los diversos eventos fisiopatológicos desencadenantes, lo cual ha mejorado su pronóstico, diagnóstico y tratamiento. Por estos constantes avances, es necesaria su frecuente revisión y análisis. La atención del paciente con insuficiencia cardíaca y episodios de congestión es compleja y crucial. Su abordaje inicia con el reconocimiento temprano de las manifestaciones clínicas, uso de métodos no invasivos diagnósticos, delimitación del perfil de congestión; consecuentemente, es necesario brindar un manejo oportuno, intensivo y eficaz que contemple el empleo temprano de diuréticos intravenosos, la evaluación de metas de descongestión y, en casos específicos, terapia diurética combinada e incluso medicamentos vasoactivos o ultrafiltración continua.


Congestion in patients with heart failure represents a manifestation of various cardiovascular structural and functional processes, associated with high morbidity and mortality and reduced quality of life, being considered the main cause of hospitalization and readmission due to heart failure. During the last decades, a better understanding of the various triggering pathophysiological events has been achieved, modifying their prognosis, diagnosis, and treatment. Due to these constant advances, its frequent review and analysis is necessary. The care of patients with heart failure and episodes of congestion is complex and crucial. Its approach begins with early recognition of clinical manifestations, use of non-invasive diagnostic methods, delimitation of the congestion profile; followed by timely, intensive, and effective management that contemplates the early use of intravenous diuretics, evaluation of decongestion goals and, in specific cases, combined diuretic therapy, and even vasoactive medications or continuous ultrafiltration.


A congestão em pacientes com insuficiência cardíaca representa manifestação de diversos processos cardiovasculares estruturais e funcionais, associada a elevada morbidade e mortalidade e redução da qualidade de vida, é considerada a principal causa de internação e reinternação por insuficiência cardíaca. Durante as últimas décadas, conseguiu-se uma melhor compreensão dos vários eventos fisiopatológicos desencadeantes, o que melhorou o seu prognóstico, diagnóstico e tratamento. Devido a esses constantes avanços, sua revisão e análise frequente se fazem necessárias. O cuidado de pacientes com insuficiência cardíaca e episódios de congestão é complexo e crucial. Sua abordagem inicia-se com reconhecimento precoce das manifestações clínicas, utilização de métodos diagnósticos não invasivos, delimitação do perfil de congestão. Consequentemente, é necessário proporcionar manejo oportuno, intensivo e eficaz que inclua o uso precoce de diuréticos intravenosos, a avaliação das metas de descongestão e, em casos específicos, terapia diurética combinada e até mesmo medicações vasoativas ou ultrafiltração contínua.


Subject(s)
Humans , Heart Failure/complications , Hyperemia/diagnosis , Hyperemia/therapy , Case Management
8.
Rev. urug. cardiol ; 39(1): e702, 2024. ilus, tab
Article in Spanish | LILACS, BNUY, UY-BNMED | ID: biblio-1565802

ABSTRACT

La creación de una fístula arteriovenosa (FAV) determina un incremento del gasto cardíaco, cuya magnitud está relacionada con el tamaño del cortocircuito. En el escenario adecuado esta puede conducir al desarrollo de insuficiencia cardíaca (IC) con alto gasto cardiaco. Se presenta el caso de un paciente que desarrolla IC luego de la confección de una FAV para hemodiálisis crónica y sus implicancias clínicas posteriores. Se revisan aspectos diagnósticos y terapéuticos referidos a la IC de alto gasto.


The creation of an arteriovenous fistula (AVF) determines an increase in cardiac output, the magnitude of which is related to the size of the shunt. In the right scenario, this can lead to the development of heart failure (HF) with high cardiac output. The case of a patient who develops HF after creating an AVF for chronic hemodialysis and its subsequent clinical implications is presented. Diagnostic and therapeutic aspects related to high-output HF are reviewed.


A criação de uma fístula arteriovenosa (FAV) determina aumento do débito cardíaco, cuja magnitude está relacionada ao tamanho do shunt. No cenário certo, isso pode levar ao desenvolvimento de insuficiência cardíaca (IC) com alto débito cardíaco. É apresentado o caso de um paciente que desenvolve IC após confecção de FAV para hemodiálise crônica e suas subsequentes implicações clínicas. Aspectos diagnósticos e terapêuticos relacionados à IC de alto débito são revisados.


Subject(s)
Humans , Male , Adult , Young Adult , Arteriovenous Fistula/surgery , Cardiac Output, High , Heart Failure/therapy , Heart Failure/diagnostic imaging
9.
Rev. latinoam. enferm. (Online) ; 32: e4302, 2024. tab
Article in English | LILACS, BDENF | ID: biblio-1569983

ABSTRACT

Abstract Objective: to identify the factors contributing to medication non-adherence among patients with heart failure. Method: cross-sectional and analytical study using the Medida de Adesão ao Tratamento [Treatment Adherence Measure] scale to assess medication non-adherence. Independent variables were collected using the European Heart Failure Self-care Behavior Scale and an instrument developed by the authors based on a previous study. Statistical tests were implemented to analyze data with p≤0.05 statistical significance. Results: the sample comprised 340 patients, with 9.4% considered non-adherent. The multiple analysis results showed that one unit increase in an individual's self-care score led to an 8% increase in the prevalence of non-adherence; patients with a family income above three times the minimum wage presented a prevalence of non-adherence equal to 3.5% of the prevalence of those with up to one times the minimum wage; individuals consuming alcohol or with depression presented 3.49 and 3.69 times higher prevalence of non-adherence, respectively, than individuals not presenting such history. Conclusion: medication non-adherence was associated with self-care, family income, depression, and alcohol consumption.


Resumo Objetivo: identificar os fatores que contribuem para a não adesão ao tratamento farmacológico de pacientes com insuficiência cardíaca. Método: estudo transversal e analítico que utilizou a escala de Medida de Adesão ao Tratamento para avaliar a não adesão ao tratamento farmacológico. Variáveis independentes foram coletadas utilizando-se a European Heart Failure Self-care Behavior Scale e um instrumento elaborado pelos autores, baseado em estudo anterior. Foram utilizados testes estatísticos para análise dos dados, sendo considerados significativos os valores de p≤0,05. Resultados: a amostra foi composta por 340 pacientes. Desses, 9,4% foram classificados como não aderentes. Os resultados da análise múltipla mostraram que o aumento de uma unidade no escore de autocuidado leva a um aumento de 8% na prevalência de não adesão do indivíduo; pacientes com renda familiar superior a três salários mínimos têm prevalência de não adesão ao tratamento igual a 3,5% da prevalência entre aqueles com até um salário mínimo; indivíduos que ingerem bebida alcoólica e sofrem de depressão têm prevalências de não adesão 3,49 e 3,69 vezes maiores, respectivamente, do que aqueles que não têm tais antecedentes. Conclusão: a não adesão ao tratamento farmacológico relacionou-se com comportamento de autocuidado, renda familiar, depressão e ingestão de bebida alcoólica.


Resumen Objetivo: identificar los factores que contribuyen para la no adhesión al tratamiento farmacológico de pacientes con insuficiencia cardíaca. Método: estudio transversal y analítico que utilizó la escala de Medida de Adhesión al Tratamiento para evaluar la no adhesión al tratamiento farmacológico. Las variables independientes fueron recolectadas utilizando la European Heart Failure Self-care Behavior Scale y un instrumento elaborado por los autores, basado en estudio anterior. Fueron utilizadas pruebas estadísticas para el análisis de los datos, siendo considerados significativos los valores de p≤0,05. Resultados: la muestra estuvo compuesta por 340 pacientes; de esos, 9,4% fueron clasificados como no adherentes. Los resultados del análisis múltiple mostraron que el aumento de una unidad en el puntaje de autocuidado lleva a un aumento de 8% en la prevalencia de la no adhesión del individuo; pacientes con renta familiar superior a tres salarios mínimos tienen prevalencia de no adhesión al tratamiento igual a 3,5% de aquellos que reciben hasta un salario mínimo; individuos que ingieren bebida alcohólica y sufren de depresión, tienen prevalencias de no adhesión de 3,49 y 3,69 veces mayores, respectivamente, que aquellos que no tienen esos antecedentes. Conclusión: la no adhesión al tratamiento farmacológico se relacionó con comportamientos de autocuidado, renta familiar, depresión e ingestión de bebida alcohólica.


Subject(s)
Humans , Male , Female , Medication Adherence , Treatment Adherence and Compliance , Heart Failure , Nursing Care
10.
Medicentro (Villa Clara) ; 27(4)dic. 2023.
Article in Spanish | LILACS | ID: biblio-1534852

ABSTRACT

Introducción: Las enfermedades cardíacas y renales coexisten con frecuencia. El síndrome cardiorrenal es una entidad compleja; en ella, la disfunción primaria cardíaca produce daño renal (tipos 1 y 2) y viceversa (tipos 3 y 4) o efecto de una enfermedad sistémica que afecta a ambos órganos (tipo 5). Objetivo: Actualizar el diagnóstico y tratamiento de los pacientes con síndrome cardiorrenal. Métodos: Se utilizan métodos teóricos y empíricos para realizar análisis del conocimiento actualizado sobre el tema. Se ha definido la existencia de un síndrome cardiorrenal que compromete a ambos órganos, con interacción bidireccional. En su detección, el diagnóstico clínico es insuficiente y requiere marcadores bioquímicos; estas herramientas, junto con la medición del sodio urinario, permite vigilar la efectividad terapéutica. Otro recurso es la ultrafiltración, según complicaciones. Conclusiones: Se debe indicar tratamiento con base en la evidencia para mejorar la calidad de vida, reducir la mortalidad y retrasar el deterioro de la función renal y cardíaca a largo plazo; el trasplante renal se debe considerar en pacientes en diálisis con disfunción ventricular severa. Idealmente, deberían recibir un trasplante combinado: cardíaco y renal, lo cual es difícil; algunos pacientes sometidos exclusivamente a trasplante renal presentan una mejoría notable en su fracción de eyección y en la sobrevida.


Introduction: heart and kidney diseases frequently coexist. Cardiorenal syndrome is a complex entity in which primary cardiac dysfunction causes a kidney damage (types 1 and 2) and vice versa (types 3 and 4) or an effect of a systemic disease that affects both organs (type 5). Objective: to update the diagnosis and treatment of patients with cardiorenal syndrome. Methods: theoretical and empirical methods are used to carry out the analysis of updated knowledge on the subject. The existence of a cardiorenal syndrome that compromises both organs has been defined with bidirectional interaction. In its detection, clinical diagnosis is insufficient and requires biochemical markers; these tools, together with the measurement of urinary sodium, allow us to monitor therapeutic effectiveness. Another resource is ultrafiltration, according to complications. Conclusions: evidence-based treatment should be indicated to improve quality of life, reduce mortality, and delay the deterioration of renal and cardiac function in the long term; kidney transplantation should be considered in dialysis patients with severe ventricular dysfunction. Ideally, they should receive a combined transplant: heart and kidney, which is difficult; some patients undergoing exclusively a renal transplantation show a notable improvement in their ejection fraction and survival.


Subject(s)
Heart Failure , Acute Kidney Injury
11.
Rev. costarric. cardiol ; 25(2): 45-50, jul.-dic. 2023. tab
Article in Spanish | LILACS, SaludCR | ID: biblio-1559766

ABSTRACT

RESUMEN Introducción y objetivos : La insuficiencia cardíaca (IC) es una preocupación creciente de salud pública. Si bien los betabloqueantes (BB) son la base del tratamiento, lograr reducciones objetivo de frecuencia cardíaca puede ser difícil debido a los efectos secundarios y la tolerancia limitada. La ivabradina, un inhibidor único de la corriente If, ofrece un enfoque complementario para controlar la frecuencia cardíaca sin afectar la contractilidad. El objetivo de este estudio fue evaluar la eficacia de agregar ivabradina a la terapia BB en pacientes con IC. Métodos: Se realizó un estudio observacional retrospectivo en un hospital privado en San José, Costa Rica se analizaron 7 casos de pacientes tratados con BB a los cuales posteriormente se les adicionó ivabradina. Se recopilaron datos demo- gráficos, las características clínicas, la frecuencia cardíaca previa y posterior a la ivabradina, la clase funcional NYHA y los valores de laboratorio seleccionados. Resultados: La ivabradina redujo significativamente la frecuencia cardíaca en reposo en un promedio de 26,87 latidos por minuto. El 42,86% alcanzó la dosis meta de su BB inicial después de agregar ivabradina. La clase funcional NYHA se mantuvo estable o mejoró en todos los casos. Conclusiones: Estos resultados sugieren que agregar ivabradina a la terapia BB puede ser una estrategia eficaz para optimizar el control de la frecuencia cardíaca en pacientes con IC. Este enfoque puede mejorar la tolerabilidad de BB, lo que lleva a un mayor manejo de la dosis meta y posiblemente mejores resultados clínicos.


ABSTRACT Introduction and objectives: Heart failure (HF) is a growing public health concern. While beta-blockers (BBs) are the cornerstone of treatment, achieving target heart rate reductions can be difficult due to side effects and limited tolerance. Ivabradine, a unique inhibitor of the If current, offers a complementary approach to controlling heart rate without affecting contractility. This study aimed to evaluate the effectiveness of adding ivabradine to BB therapy in patients with HF. Methods : A retrospective observational study was conducted at a private hospital in San José, Costa Rica. Seven cases of patients treated with BBs who were subsequently added to ivabradine were analyzed. Demographic data, clinical characteristics, heart rate before and after ivabradine, NYHA functional class, and selected laboratory values were collected. Results : Ivabradine significantly reduced resting heart rate by an average of 26.87 beats per minute. Forty-two-point eight-six percent (42.86%) achieved the target dose of their initial BB after adding ivabradine. NYHA functional class remained stable or improved in all cases. Conclusions: These results suggest that adding ivabradine to BB therapy may be an effective strategy to optimize heart rate control in patients with HF. This approach may improve BB tolerability, leading to greater target dose management and possibly better clinical outcomes.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Ivabradine/therapeutic use , Heart Failure/drug therapy , Costa Rica
12.
Rev. chil. cardiol ; 42(3): 143-152, dic. 2023. tab, ilus, graf
Article in Spanish | LILACS | ID: biblio-1529981

ABSTRACT

Antecedentes: La ECA2 ha mostrado ser un regulador esencial de la funcionalidad cardíaca. En un modelo experimental de insuficiencia cardíaca (IC) con Fier, modelo de coartación de aorta (COA), se encontró activación de la vía Rho-kinasa. La inhibición de esta vía con fasudil no mejoró el remodelado cardíaco ni la disfunción sistólica. Se desconoce en este modelo, si el deterioro de la función cardíaca y activación de la vía rho-kinasa se asocia con una disminución de la ECA2 cardíaca y si la inhibición de Rho-kinasa tiene un efecto sobre la expresión de ECA2. Objetivo: Nuestro objetivo es determinar si en la falla cardaca experimental por coartación aórtica, los niveles proteicos de ECA2 en el miocardio se asocian a disfunción sistólica y cual es su interacción con la actividad de ROCK en el miocardio. Métodos: Ratones C57BL6J machos de 7-8 semanas se randomizaron en 3 grupos experimentales. Grupo COA por anudación de la aorta + vehículo; Grupo COA + Fasudil (100 mg/Kg día) por bomba osmótica desde la semana 5 post-cirugía; y grupo control o Sham. Se determinaron las dimensiones y función cardíaca por ecocardiografía. Posterior a la eutanasia, se determinaron los niveles de ECA2 del VI por Western-blot y actividad de la Rho-kinasa Resultados: En los grupos COA+vehículo y COA-FAS hubo deterioro de la función cardíaca, reflejada por la reducción de la FE (47,9 ± 1,53 y 45,5 ± 2,10, p < 0,05, respectivamente) versus SHAM (68,6 ± 1,19). Además, aumentaron las dimensiones cardíacas y hubo desarrollo de hipertrofia (0,53 ± 0,02 / 0,53 ± 0,01, p < 0,05) medida por aumento de la masa cardíaca relativa respecto del grupo SHAM (0,40 ± 0,01). En los grupos COA+vehículo y COA-FAS se encontró una disminución significativa del 35% en la expresión de ECA2 cardíaca respecto al grupo control. Conclusiones: La disfunción sistólica por coartación aórtica se asocia con aumento de la actividad de Rho-kinasa y significativa disminución de la expresión de ECA2. La inhibición de Rho-kinasa no mejoró el remodelado cardíaco, la disfunción sistólica y tampoco modificó los niveles de ECA2 cardíaca.


Background: ACE2 has been described as an essential regulator of cardiac function. In an experimental model of heart failure (HF) and heart failure reduced ejection fraction (HFrEF), the aortic coarctation (COA) model, activation of the Rho-kinase pathway of cardiac remodeling was found. Inhibition of this pathway did not improve cardiac remodeling or systolic ventricular dysfunction. It is unknown in this model whether the impairment of cardiac function and activation of the rho-kinase pathway is associated with a decrease in ACE2 and whether rho-kinase inhibition has an effect on ACE2 expression. Objective: To determine if in experimental heart failure due to aortic coarctation, ACE2 protein levels in the myocardium are associated with systolic dysfunction and what is its interaction with ROCK activity in the myocardium. Methods: Male C57BL6J mice aged 7-8 weeks were divided into 3 groups and anesthetized: One group underwent COA+ vehicle; A second group COA + Fasudil (100 mg/Kg/d) by osmotic pump from week 5 post-surgery and; the third group, control(SHAM). Echocardiograms were performed to determine cardiac dimensions and systolic function. Rats were then euthanized. Ventricular expression of ACE2, activity of the Rho-kinase pathway by MYPT-1 phosphorylation, relative cardiac mass, area and perimeter of cardiomyocytes were determined by Western blot. Results: In both COA+vehicle and COA+FAS groups there was deterioration of cardiac function, reflected in the reduction of EF (47.9 ± 1.53 and 45.5 ± 2.10, p < 0.05, respectively) versus the SHAM group (68.6 ± 1.19). In addition, cardiac dimensions and hypertrophy increased (0.53 ± 0.02 / 0.53 ± 0.01, p < 0.05) due to increased relative cardiac mass compared to the SHAM group (0.40 ± 0.01). In the COA+vehicle and COA+FAS groups a significant decrease of 35% in cardiac ACE2 expression was found compared to the control group. Conclusions: Systolic dysfunction due to aortic coarctation is associated with increased Rhokinase activity and a significant decrease in ACE2 expression. Rho-kinase inhibition did not improve cardiac remodeling, systolic dysfunction, nor did it change cardiac ACE2 levels.


Subject(s)
Animals , Mice , Angiotensin-Converting Enzyme 2 , Heart Failure/enzymology , Aortic Coarctation , Blotting, Western , Hypertrophy, Left Ventricular , Ventricular Dysfunction, Left , Disease Models, Animal , Mice, Inbred C57BL
13.
Acta méd. costarric ; 65(4): 173-180, oct.-dic. 2023. tab
Article in Spanish | LILACS, SaludCR | ID: biblio-1568731

ABSTRACT

Resumen La insuficiencia cardiaca aguda es una emergencia que aumenta la mortalidad cardiovascular debido a los síntomas y signos de congestión e hipoperfusión vascular. El manejo actual con diuréticos, inotrópicos y vasopresores mejora el estado clínico; sin embargo, la morbimortalidad asociada a esta patología sigue siendo altamente significativa. Por otra parte, los inhibidores del cotransportador sodio-glucosa tipo 2 (iSGLT2) han demostrado una reducción en la hospitalización y mortalidad cardiovascular en los pacientes con insuficiencia cardiaca crónica. Por ende, el objetivo de este artículo es analizar los efectos clínicos de este grupo farmacológico en la insuficiencia cardiaca aguda, con base en investigaciones científicas. Los hallazgos de estas investigaciones demostraron un beneficio clínico de los iSGLT2 sobre esta patología, con base a parámetros como mortalidad, hospitalización, eventos clínicos, función renal, efecto diurético y concentraciones del biomarcador NT-proBnp, los cuales se detallarán en el presente artículo. Por consiguiente, se concluyó que estos fármacos son seguros sobre la evolución clínica de la insuficiencia cardiaca aguda.


Abstract Acute heart failure is an emergency that increases cardiovascular mortality due to symptoms and signs of vascular congestion and hypoperfusion. Current management with diuretics, inotropes, and vasopressors improves the clinical status; However, the morbidity and mortality associated with this pathology remains highly significant. On the other hand, sodium-glucose cotransporter 2 (SGLT2i) inhibitors have shown a reduction in hospitalization and cardiovascular mortality in patients with chronic heart failure. Therefore, the objective of this article is to analyze the clinical effects of this pharmacological group in acute heart failure, based on scientific research. The findings of these investigations demonstrated a clinical benefit of SGLT2i on this pathology, based on parameters such as mortality, hospitalization, clinical events, renal function, diuretic effect and concentrations of the NTproBnp biomarker, which will be detailed in this article. Therefore, it was concluded that these drugs are safe on the clinical course of acute heart failure.


Subject(s)
Humans , Male , Female , Sodium-Glucose Transporter 2 Inhibitors/therapeutic use , Heart Failure/drug therapy
14.
J. bras. econ. saúde (Impr.) ; 15(2): 98-108, Agosto/2023.
Article in English, Portuguese | ECOS, LILACS | ID: biblio-1518868

ABSTRACT

Objetivo: Avaliar a relação de custo-efetividade e impacto orçamentário (AIO) do tratamento de deficiência de ferro (DF), com ou sem anemia, em pacientes com insuficiência cardíaca (IC) com fração de ejeção reduzida NYHA II e III, com uso de carboximaltose férrica (CMF), comparada ao placebo (não intervenção), sob a perspectiva pagadora da saúde suplementar (SS). Métodos: No modelo econômico, foi utilizada a árvore de decisão, no horizonte temporal de 52 semanas, na perspectiva da SS, sendo mensurados os benefícios clínicos e os custos associados à intervenção. Também foram executadas análises de sensibilidade determinística e probabilística para avaliar possíveis incertezas futuras. A elaboração da AIO foi realizada considerando o horizonte temporal de cinco anos, a população a ser tratada, os diferentes cenários de market share e os custos diretos envolvidos no tratamento atual e no tratamento proposto. Resultados: A razão de custo-efetividade incremental (RCEI) foi de -R$ 20.517,07 para um ano de vida ajustado pela qualidade (QALYs). O impacto da incorporação da CMF na SS gerou uma economia em cinco anos de -R$ 43.945.225. Conclusões: A análise apresentada mostrou que o tratamento com CMF reduziu o custo de hospitalização, o número de consultas ambulatoriais e o custo de outros medicamentos relacionados à IC e proporcionou uma economia anual. Considerando um horizonte de tempo de 52 semanas, a terapia intravenosa com CMF resultou em uma estratégia de redução de custos, quando comparada ao tratamento proposto para a DF em pacientes com IC.


Objective: This study aims to evaluate the cost-effectiveness and budget impact (AIO) of iron carboxymaltose (CMF) for treatment of iron deficiency (ID), with or without anemia, in patients with heart failure (HF) and reduced ejection fraction NYHA II and III compared to placebo (non-intervention), from the perspective of paying supplementary health (SS). Methods: In the economic model, the decision tree was used, with a time horizon of 52 weeks, from the SS perspective, measuring the clinical benefits and costs associated with the intervention. Deterministic and probabilistic sensitivity analyzes were also performed to assess possible future uncertainties. The elaboration of the AIO was carried out considering a time horizon of five years, population to be treated, different market share scenarios and direct costs involved in the current treatment and in the proposed treatment. Results: The incremental cost effectiveness ratio (ICER) was -R$ 20,517.07 for 1 quality-adjusted life year (QALY). The budget impact of incorporation of the CMF in SSprovided savings in five years of -R$ 43,945,225. Conclusions: The presented analysis showed that treatment with CMF reduced the cost of hospitalization, the number of outpatient visits and the cost of other HF-related medications and provided annual savings. Considering a time horizon of 52 weeks, intravenous therapy with CMF resulted in a cost-saving strategy when compared to the proposed treatment for DF in patients with HF.


Subject(s)
Analysis of the Budgetary Impact of Therapeutic Advances , Iron Deficiencies , Cost-Effectiveness Analysis , Heart Failure
15.
Oncología (Guayaquil) ; 33(2): 107-111, 14 de agosto del 2023.
Article in Spanish | LILACS | ID: biblio-1451543

ABSTRACT

Introducción: Las enfermedades cardiovasculares son la principal causa de muerte en el mundo, y las enfermedades oncológicas están aumentando en prevalencia. Los medicamentos oncológicos pueden tener efectos secundarios cardiovasculares, y la cardiooncología es una subespecialidad de la cardiología que se ocupa de la prevención y el tratamiento de las complicaciones cardiovasculares relacionadas con el cáncer. Puntos importantes del editorial: Las antraciclinas son un grupo de medicamentos oncológicos que pueden causar cardiotoxicidad, lo que puede causar una variedad de síntomas, incluyendo fatiga, disnea, edema y dolor en torácico. En casos graves, la cardiotoxicidad puede provocar insuficiencia cardíaca. Otros medicamentos oncológicos que pueden causar cardiotoxicidad incluyen los anticuerpos anti-HER2, el fluorouracilo y la gemcitabina. Los inhibidores de la tirosinkinasa y los inhibidores del factor de crecimiento derivado del endotelio también pueden causar problemas cardiovasculares, como hipertensión, formación de coágulos sanguíneos y arritmia. Los pacientes con cáncer también tienen un mayor riesgo de desarrollar complicaciones tromboembólicas venosas en miembros inferiores. Conclusión: El diagnóstico temprano y el tratamiento de las complicaciones cardiovasculares relacionadas con el cáncer son esenciales para mejorar la supervivencia de los pacientes con cáncer. La cardiooncología es una especialidad emergente y multidisciplinaria que requiere la participación de oncólogos, hematólogos, radiooncólogos y cardiólogos. El equipo de cardiooncología trabaja en conjunto para evaluar el riesgo cardiovascular de los pacientes con cáncer, prevenir las complicaciones cardiovasculares y tratar las complicaciones cardiovasculares que ocurren.


Introduction: Cardiovascular diseases are the main cause of death in the world, and oncological diseases are increasing in prevalence. Cancer drugs can have cardiovascular side effects, and cardio-oncology is a subspecialty of cardiology concerned with preventing and treating cardiovascular complications related to cancer. Important points from the editorial: Anthracyclines are a group of cancer drugs that can cause cardiotoxicity, which can cause various symptoms, including fatigue, dyspnea, edema, and chest pain. In severe cases, cardiotoxicity can lead to heart failure. Other cancer drugs that can cause cardiotoxicity include anti-HER2 antibodies, fluorouracil, and gemcitabine. Tyrosine kinase and endothelium-derived growth factor inhibitors can also cause cardiovascular problems, such as high blood pressure, blood clot formation, and arrhythmia. Cancer patients are also at increased risk of developing lower limb venous thromboembolic complications. Conclusion: Early diagnosis and treatment of cancer-related cardiovascular complications are essential to improve the survival of cancer patients. Cardio-oncology is an emerging, multidisciplinary specialty that requires the participation of oncologists, hematologists, radiation oncologists, and cardiologists. The cardio-oncology team works together to assess cardiovascular risk in cancer patients, prevent cardiovascular complications, and treat cardiovascular complications that do occur.


Subject(s)
Humans , Adult , Integrative Oncology , Myocarditis , Cardiology , Heart Failure
16.
Med. UIS ; 36(2)ago. 2023.
Article in Spanish | LILACS | ID: biblio-1534839

ABSTRACT

Introducción: la adherencia a estándares de manejo en insuficiencia cardiaca como la iniciativa Get With the Guidelines (GWTG) de la AHA puede disminuir los reingresos y mortalidad. Objetivo: describir las características clínicas de pacientes hospitalizados por insuficiencia cardiaca aguda y evaluar la adherencia a estándares de práctica clínica del programa "Get With The Guidelines", en un hospital universitario de Bogotá. Materiales y métodos: estudio observacional de la cohorte retrospectiva HUN-ICA correspondiente a 493 pacientes adultos hospitalizados entre abril 2016 y diciembre 2018 por insuficiencia cardiaca aguda, se registraron variables clínicas, tratamiento, mortalidad, reingresos y se evaluó adherencia a estándares de calidad del programa GWTG. Resultados: 52,1 % de la población fueron mujeres con una media de edad 75 años y el 67,8 % con FEVI >40 %. La etiología más común fue hipertensiva 58,5 % y la mayor causa de descompensación infecciosa (28,8 %). Aumentó la adherencia al uso de betabloqueadores en pacientes con fracción de eyección reducida al egreso de 46 % respecto al ingreso y al uso de antagonistas de receptor mineralocorticoide en pacientes con FEVI reducida de 61,1 %. Discusión: la cohorte evaluada presentó un perfil hemodinámico, clínico y adherencia en el manejo similar a cohortes nacionales. Las dosis subóptimas de la medicación al egreso justifican la necesidad de clínicas ambulatorias de insuficiencia cardíaca. Conclusiones: Se encontró menor adherencia para uso y dosis óptimas de betabloqueadores y antagonista mineralocorticoide que la de la cohorte GWTG, con incremento del uso de terapia farmacológica entre el ingreso y el egreso hospitalario.


Introduction: adherence to management standards in heart failure such as the AHA´s Get With the Guidelines-Heart failure initiative can reduce readmissions and mortality. Objective: To describe the clinical characteristics of patients hospitalized for acute heart failure and to assess adherence to program quality standards of the Get With The Guidelines Program in a university hospital in Bogotá. Methods: observational, descriptive and retrospective HUN-ICA cohort study. 493 adult patients hospitalized for acute heart failure, between April 2016 to December 2018. Clinical variables, treatment, mortality, readmissions and adherence to program quality standards defined by the GWTG program criteria were evaluated. Results: 52,1 % of the population were women, mean age was 75 years, (67,8 %) cases of heart failure with LVEF > 40 %. The most common etiology of heart failure was hypertensive (58,5 %). The most frequent etiology of decompen- sation was infectious (28,8 %). Adherence to beta-blockers use increased in patients with reduced ejection fraction at discharge of 46 %, and to the use of mineralocorticoid receptor antagonists in 61,1 %, compared to admission. Discussion: the evaluated cohort presented a hemodynamic, clinical profile and adherence similar to colombian cohorts. Suboptimal doses of medication upon discharge justify the need for outpatient heart failure clinics. Conclusions: lower adherence for use and optimal doses of beta-blockers and mineralocorticoid receptor antagonists than GWTG cohort was found, with increased use of guidelines recommended pharmacological therapy between hospital admission and discharge.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Guideline Adherence , Heart Failure , Patient Readmission , Practice Guideline , Treatment Adherence and Compliance
17.
Rev. Asoc. Med. Bahía Blanca ; 33(1): 29-32, jun. 2023.
Article in Spanish | LILACS, UNISALUD, BINACIS | ID: biblio-1436106

ABSTRACT

Introducción: La tirotoxicosis se considera una emergencia endocrinológica. Suele ser la complicación más grave y menos frecuente de una patología relativamente frecuente como es el hipertiroidismo. Tiene afectación a nivel sistémico, con especial hincapié en el sistema cardiovascular, por lo que una de las manifestaciones prevalentes y a considerar en este trabajo, es la insuficiencia cardiaca aguda. Caso clínico: Paciente femenina de 40 años con antecedente de tabaquismo e hipertiroidismo, con abandono de medicación (Metimazol) y de controles en contexto de pandemia. Consultó en reiteradas ocasiones por evento sincopal asociado a palpitaciones, agregando en esta consulta episodio tos con expectoración hemoptoica y náuseas. Laboratorio con TSH<0.01mU/L y T4 7.77pmol/L. Troponinas 19.3ng/L. Evolucionó con hipotensión sin respuesta a cristaloides y mayor disnea. Se decidió intubación orotraqueal. Se realizó ecocardiograma que informaba función sistólica con deterioro severo. Realizó tratamiento con Metimazol y solución de Lugol con mejoría de los parámetros de laboratorio. A los diez días evolucionó con abdomen agudo perforado con posterior shock séptico refractario y falleció. Discusión y conclusiones: Luego de examinar la bibliografía disponible, y contrastarla de forma retrospectiva con la evolución de la paciente, se puede observar la relación entre el hipertiroidismo y los cambios hemodinámicos. En el caso presentado, la paciente tuvo como antecedente el diagnóstico de hipertiroidismo y se consideró que el factor desencadenante fue la suspensión del metimazol; a su vez, la insuficiencia cardíaca aguda que presentó durante los primeros días de internación fue consecuencia del efecto cardiovascular directo de las hormonas tiroideas.


Introduction: Thyrotoxicosis is considered an endocrinological emergency; It is usually the most serious and least frequent complication of a relatively frequent pathology such as hyperthyroidism. It has systemic involvement, with special emphasis on the cardiovascular system, which is why one of the most prevalent manifestations to be considered in this work is acute heart failure. Clinical case: A 40-year-old female patient with a history of smoking and hyperthyroidism, with abandonment of medication (Methimazole) and controls in the context of a pandemic. She consulted repeatedly due to a syncopal event associated with palpitations, adding to this consultation an episode of coughing with bloody sputum and nausea. Laboratory with TSH <0.01mU/L and T4 7.77pmol/L. Troponins 19.3ng/L. He evolved with hypotension without response to crystalloids and increased dyspnea. Orotracheal intubation was decided. An echocardiogram was performed, which reported severely impaired systolic function. She underwent treatment with Methimazole and Lugol's solution with improvement in laboratory parameters. Ten days later, he developed an acute perforated abdomen with subsequent refractory septic shock and died. Discusion. Conclusion: After examining the available bibliography, and contrasting it retrospectively with the evolution of the patient, the relationship between hyperthyroidism and hemodynamic changes can be observed. In the case presented, the patient had a history of a diagnosis of hyperthyroidism, and it was considered that the triggering factor was the suspension of methimazole; In turn, the acute heart failure that she presented during the first days of hospitalization was a consequence of the direct cardiovascular effect of thyroid hormones.


Subject(s)
Thyrotoxicosis , Heart Failure , Hyperthyroidism
19.
Rev. Ciênc. Méd. Biol. (Impr.) ; 22(1): 37-46, jun 22, 2023. tab, fig
Article in Portuguese | LILACS | ID: biblio-1442836

ABSTRACT

Introdução: a insuficiência cardíaca (IC) e a sarcopenia são condições prevalentes e inter-relacionadas, figurando como importantes causas de limitações funcionais. Objetivo: avaliar critérios de sarcopenia, e suas relações com parâmetros cardiometabólicos, em pacientes de 40 a 64 anos hospitalizados por IC. Metodologia: estudo de corte transversal com caráter analítico envolvendo indivíduos com IC confirmada. A massa muscular apendicular (MMA) foi avaliada através da absorciometria por raios-X de dupla energia (DXA), considerando-se baixa MMA mulheres com MMA/altura² <5,5 kg/m² ou MMA/índice de massa corporal (IMC) <0,512 e homens com MMA/altura² <7,0 kg/m² ou MMA/IMC <0,789. Baixa força de preensão manual (FPM) foi considerada quando <16 kg em mulheres e <27 kg em homens. Resultados: avaliou-se 109 pacientes (50,5% mulheres), com mediana de idade de 58 anos. Constatou-se baixa MMA em 41,3% e baixa FPM em 64,2%, não havendo correlação significativa entre FPM e MMA em nenhum dos gêneros. Baixa MMA se associou ao gênero masculino (68,9% versus 35,9%; p=0,001), a maiores idades (60,0 [53,0-63,0] versus 57,0 [51,3-60,0] anos; p=0,039) e maiores níveis séricos de paratormônio (48,0 [30,5-94,4] versus 29,9 [23,0-54,1] pg/mL; p=0,009). Baixa FPM se associou a maior sintomatologia cardíaca (75,7% com baixa FPM tinham classificação funcional da New York Heart Association III-IV, versus 51,3% daqueles com FPM normal; p=0,009). Conclusões: há uma relevante prevalência de sarcopenia em pacientes de 40 a 64 anos hospitalizados por IC, observando-se maior frequência de baixa MMA nos homens, associação entre baixa FPM e sintomatologia cardíaca, e maiores níveis de paratormônio naqueles com perda muscular.


Introduction: heart failure (HF) and sarcopenia are prevalent and interrelated conditions, being important causes of functional limitations. Objective: to evaluate sarcopenia criteria, and their relationship with cardiometabolic parameters, in patients aged 40­64 years hospitalized for HF. Methodology: Cross-sectional study including patients with established HF. Appendicular skeletal muscle mass (ASMM) was assessed using dual-energy X-ray absorptiometry (DXA), considering low ASMM women with ASMM/height² <5.5 kg/m² or ASMM/body mass index (BMI) <0.512 and men with ASMM/height² <7.0 kg/m² or ASMM/BMI <0.789. Low handgrip strength (HGS) was considered when <16 kg in women and <27 kg in men. Results: we evaluated 109 patients (50.5% women), with a median age of 58 years. Low ASMM was found in 41.3% and low HGS in 64.2%, with no significant correlation between HGS and ASMM in either gender. Low ASMM was associated with male gender (68.9% versus 35.9%; p=0.001), older age (60.0 [53.0-63.0] versus 57.0 [51.3-60, 0] years; p=0.039) and higher serum parathyroid hormone (48.0 [30.5-94.4] versus 29.9 [23.0-54.1] pg/mL; p=0.009). Low HGS was associated with greater cardiac symptoms (75.7% with low HGS had a New York Heart Association III-IV functional classification, versus 51.3% of those with normal HGS; p=0.009). Conclusions: there is a relevant prevalence of sarcopenia in patients aged 40­64 years hospitalized for HF, observing a higher frequency of low ASMM in men, an association between low HGS and cardiac symptoms, and higher levels of parathyroid hormone in those with muscle wasting.


Subject(s)
Humans , Male , Female , Pregnancy , Middle Aged , Muscle Strength , Sarcopenia , Heart Failure , Laboratory and Fieldwork Analytical Methods , Cross-Sectional Studies
20.
Article in Spanish | LILACS, CUMED | ID: biblio-1536317

ABSTRACT

Introducción: La insuficiencia cardíaca tiene un gran impacto epidemiológico, no solo por su alta morbilidad y mortalidad, sino también por el alto costo en servicios hospitalarios. Las tasas de hospitalización por reagudizaciones y readmisiones luego del alta se han incrementado los últimos años, lo que constituye en la actualidad un problema de salud pública. Objetivo: Evaluar el efecto de la intervención de la telemedicina en pacientes peruanos con insuficiencia cardíaca en tiempos de COVID-19. Métodos: Se utilizó un diseño cuasi experimental con evaluación antes y después de la intervención en 32 pacientes provenientes de Chimbote (Perú), entre los meses de enero a junio del 2021, que aceptaron participar en el estudio y cumplieron con los criterios de inclusión y exclusión. Se utilizó una ficha de recolección de datos que registró las características clínicas de los pacientes, frecuencia de hospitalización y clase funcional, así como el cuestionario de Kansas City que midió la calidad de vida relacionada a salud. En la intervención, se implementaron actividades de telemedicina que comprendió teleconsulta médica de cardiología, telemonitoreo y teleorientación de enfermería, y teleorientación de nutrición. Resultados: Se redujo la frecuencia de hospitalización de 9,4 por ciento a 0 por ciento en los pacientes categorizados en clase funcional III disminuyó de 28,1 por ciento a 15,6 por ciento, y el score general se mejoró de 65,8 a 69,6 puntos. Conclusiones: La intervención de la telemedicina mejoró los resultados sanitarios de los pacientes peruanos con insuficiencia cardíaca(AU)


Introduction: Heart failure has a great epidemiological impact, not only because of its high morbidity and mortality, but also because of the high cost in hospital services. Hospitalization rates for exacerbations and readmissions after discharge have increased in recent years, which is currently a public health problem. Objective: To evaluate the effect of telemedicine intervention in Peruvian patients with heart failure in COVID-19 times. Methods: A quasi-experimental design was used with evaluation before and after the intervention in 32 patients from Chimbote (Peru), between January and June 2021, who agreed to participate in the study and met the inclusion and exclusion criteria. A data collection form was used to record the clinical characteristics of the patients, frequency of hospitalization and functional class, as well as the Kansas City questionnaire that measured health-related quality of life. Telemedicine activities were implemented in the intervention, including cardiology medical teleconsultation, telemonitoring and nursing tele-guidance, and nutrition tele-guidance. Results: The frequency of hospitalization was reduced from 9.4 to 0 percent, while in patients categorized in functional class III it decreased from 28.1 to 15.6 percent. The overall score was improved from 65.8 to 69.6 points. Conclusions: The telemedicine intervention improved health outcomes in Peruvian patients with heart failure(AU)


Subject(s)
Humans , Male , Telemedicine/methods , Remote Consultation/methods , Telemonitoring , Teleorientation , COVID-19/epidemiology , Heart Failure/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL